미국 국방부, 이란 전쟁 추가 예산 800억 달러 요청
Billions More Needed for Iran War Trump Started, Pentagon Says - The New Republic
방위예산 증액이 있지만, 전쟁에 대한 반대와 정치적 불확실성으로 인해 시장 반응이 미미할 것으로 보입니다. 따라서 중립적인 입장을 유지하는 것이 타당합니다.
핵심 요약
미국 국방부는 이란 전쟁 추가 예산으로 800억 달러를 요청하며, 백악관은 2027년 국방예산을 1.5조 달러로 제안했습니다.
핵심요약
- 미국 국방부는 이란 전쟁 추가 예산으로 800억 달러를 요청함
- 2027년 국방예산은 현재 대비 50% 증가한 1.5조 달러로 제안됨
- initially, 전쟁 비용은 290억 달러로 추정되었으나, 이는 파괴된 군사 시설 복구 비용을 포함하지 않았음
- initially, 전쟁 비용은 2000억 달러로 예상되었음
- 이 전쟁은 미국 국민의 다수에게 반대를 받고 있음
도입
이번 기사는 미국 국방부의 추가 예산 요청과 이란 전쟁 비용에 대한 논란을 다룹니다. 이는 투자자에게 중요한 의미를 가집니다. 특히, 국방예산 증가와 관련된 부문에서 투자 기회나 리스크를 파악하는 데 도움이 될 수 있습니다.
본문 1: 국방예산 증가의 경제적 영향
미국 국방부는 이란 전쟁 비용을 커버하기 위해 추가로 800억 달러를 요청하고 있습니다. 이는 2027년 국방예산이 현재 대비 50% 증가한 1.5조 달러로 제안된 것과 함께, 군사 산업에 대한 투자가 증가할 가능성을 시사합니다. 그러나, 이는 동시에 다른 부문에서의 예산 감축을 의미하며, 특히 주택, 의료, 친환경 에너지 프로그램에 대한 예산이 줄어들 수 있습니다. 이는 관련 산업에 부정적인 영향을 미칠 수 있습니다.
본문 2: 정치적 반대의 가능성
이란 전쟁은 미국 국민의 다수에게 반대를 받고 있습니다. 이는 의회에서 추가 예산이 승인되지 않을 가능성을 높입니다. 또한, 국방부 장관의 의회에서의 증언에서도 전쟁 비용에 대한 추정치가 크게 달라지는 모습을 보였습니다. 이는 정책의 불확실성을 높이고, 군사 산업에 대한 투자의 리스크를 증가시킵니다.
본문 3: 장기적인 전망
장기적으로, 이란 전쟁의 비용과 관련된 논란은 지속될 가능성이 있습니다. 특히, 전쟁 비용이 계속 증가할 경우, 미국 정부의 재정 적자가 확대될 수 있습니다. 이는 미국 경제에 부정적인 영향을 미칠 수 있으며, 특히 국채 시장에서의 신뢰도를 떨어뜨릴 수 있습니다. 따라서, 투자자는 이러한 리스크를 고려하여 투자 결정을 내릴 필요가 있습니다.
결론
미국 국방부의 추가 예산 요청과 이란 전쟁 비용에 대한 논란은 군사 산업과 관련된 투자에 중요한 영향을 미칠 수 있습니다. 그러나, 정치적 반대의 가능성과 장기적인 재정 적자의 확대라는 리스크를 고려할 필요가 있습니다. 향후, 의회에서의 추가 예산 승인 여부와 전쟁 비용의 추가 증가 가능성을 주의 깊게 관찰할 필요가 있습니다.
Original Article
Billions More Needed for Iran War Trump Started, Pentagon Says - The New Republic
The Pentagon wants $80 billion from Congress, mostly to cover the cost of the U.S. war against Iran, the Associated Press reports.
This is on top of the White House’s request to boost defense spending in the 2027 budget to $1.5 trillion—nearly 50 percent more than current allocations. Increased military spending in the budget would come alongside cuts to housing, health care, and green energy programs.
Given that, it’s even more galling that Defense Secretary Pete Hegseth has been reportedly making his way around Capitol Hill, asking senators for an additional $80 billion to cover war expenses.
When Hegseth testified to Congress last month, he estimated that war costs would be around $29 billion—far lower than today’s asking price. But that estimate didn’t include the cost to repair or rebuild damaged U.S. military sites in the region, which may require extra cash, according to the AP .
However, the estimates for how much this war will cost American taxpayers have been all over the place: The Pentagon’s initial estimate was a whopping $200 billion. Whether Hegseth will actually get this money is a different story. The Iran war is opposed by a majority of Americans , and the Pentagon may struggle to get congressional support.
“You’re spending families’ hard-earned tax dollars on a war that many strongly oppose,” Democratic Senator Patty Murray told Hegseth last month.
Hawaii Senator Brian Schatz hasn’t polled his fellow Democrats, but he told the AP, “I haven’t found anyone who wants to do this.”
President Donald Trump’s acting Director of National Intelligence, Bill Pulte, has wasted no time purging staff members from his new office.
Pulte, a housing regulator with no experience working in intelligence, has already begun implementing sweeping personnel changes in the intelligence community.
“The deep state firings have begun,” a source familiar with the matter told NBC News . Pulte formally assumed his new post on Friday, and the firings reportedly began Monday.
These are significant changes made by a temporary lackey. Pulte has none of the military or intelligence background necessary to lead ODNI, instead making his name by targeting the president’s political enemies while leading the Federal Housing Finance Agency.
The day before Pulte started at his new post, he directed ODNI staff members to identify 400 employees to be fired from the National Counterterrorism Center in the coming weeks, another source told NBC News. The agency was previously headed by Joe Kent, who abruptly resigned earlier this year in opposition to Trump’s war in Iran. CNN reported that Pulte had requested a list of every employee at ODNI so he could determine who to purge.
Earlier this month, Trump selected Pulte’s permanent replacement: Jay Clayton, the U.S. attorney for the Southern District of New York responsible for the shoddy redactions in the government’s files on Jeffrey Epstein. The president then upended Clayton’s Senate confirmation hearing, messing up Republicans’ chances at renewing a key spy bill.
A special 79-year-old man has received unparalleled access to Eli Lilly’s obesity drug.
Millions of Americans are eagerly awaiting access to retatrutide, a powerful new drug from the pharmaceutical company. But one unidentified person has been able to gain premature access to the drug via the FDA’s “compassionate use” program, STAT reported Tuesday.
The FDA program is designed to prioritize access to experimental drugs for patients with grave or life-threatening medical issues. And while the name of the individual is not known, several signs indicate that they are likely very well connected.
A senior clinician at the National Institutes of Health, Ranganath Muniyappa, requested access to the drug for the unnamed patient in April. Muniyappa cited a diagnosis of refractory obesity with obstructive sleep apnea and pulmonary hypertension, a potentially life-threatening disease characterized by high blood pressure in the lungs. The request reportedly drew the attention of top health officials, which STAT noted was indicative of the patient’s influence.
Based on the vague parameters of the patient’s identity, STAT reached out to the White House to see if the recipient could possibly be Donald Trump, who similarly suffers from obesity and has publicly expressed interest in obesity drugs. The White House did not explicitly deny the patient was Trump.
When asked if Trump was the 79-year-old man in question, White House spokesperson Kush Desai did not say no, and instead referred STAT to the Department of Health and Human Services. When asked if Trump had obstructive sleep apnea and pulmonary hypertension, Desai offered Trump’s latest medical evaluation as a counter, which he falsely claimed “covers this,” according to STAT. It does not—the memo makes no mention of either disease.
HHS did not address the issue of the retatrutide application or the patient’s identity.
“The FDA supports expanded access programs that can provide patients with serious or life-threatening conditions access to investigational treatments when no comparable or satisfying approved therapies are available,” HHS spokesperson Emily Hilliard told STAT. “Each request is reviewed on a case-by-case basis based on the clinical circumstances and applicable statutory and regulatory requirements.”
Whoever the patient is, they had been previously treated with other obesity drugs such as tirzepatide, though sources who spoke with STAT indicated the patient experienced only moderate weight loss as a result. Muniyappa reportedly recommended against bariatric surgery because of the patient’s age and co-morbidities.
The Trump Justice Department planned to subpoena journalists at The Washington Post and The Wall Street Journal , attempting to force them to testify before a grand jury for vague national security concerns. The subpoenas were eventually withdrawn this month without any explanation after news organizations pushed back.
This was an extremely unprecedented decision that follows the all-too-familiar trend of weaponizing the DOJ against whomever President Trump is upset by that day.
Washington Post reporter Ellen Nakashima—who covers the security and intelligence community, including the war on Iran—was subpoenaed this spring. The Post was in the process of fighting Nakashima’s subpoena before the DOJ suddenly rescinded it.